Aspergillus flavus Infections in Children with Leukemia despite Liposomal Amphotericin-B Prophylaxis

Nadja Hawwa Vissing; Birgitte Lausen; Marianne Hutchings Hoffmann; Bodil Als-Nielsen; Kjeld Schmiegelow; Jannik Helweg-Larsen; Maiken Cavling Arendrup; Ulrikka Nygaard

doi:10.1097/INF.0000000000003189

Aspergillus flavus Infections in Children with Leukemia despite Liposomal Amphotericin-B Prophylaxis

Nadja Hawwa Vissing^*, Birgitte Lausen, Marianne Hutchings Hoffmann, Bodil Als-Nielsen, Kjeld Schmiegelow, Jannik Helweg-Larsen, Maiken Cavling Arendrup, Ulrikka Nygaard

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

4 Citationer (Scopus)

Abstract

Liposomal amphotericin-B (L-AmB) prophylaxis is used in children with leukemia when azoles are contraindicated, but its effect is debated. We reviewed cases of invasive aspergillosis despite L-AmB 2.5 mg/kg twice weekly in children with high-risk leukemia during 2012-2019. Ten (16%) of 62 children had proven or probable aspergillosis. Thus, L-AmB prophylaxis offered insufficient protection for Aspergillus, in particular for Aspergillus flavus.

Originalsprog	Engelsk
Tidsskrift	Pediatric Infectious Disease Journal
Vol/bind	40
Udgave nummer	8
Sider (fra-til)	749-752
Antal sider	4
ISSN	0891-3668
DOI	https://doi.org/10.1097/INF.0000000000003189
Status	Udgivet - 2021

Bibliografisk note

Publisher Copyright:
© 2021 Wolters Kluwer Health, Inc. All rights reserved.

Adgang til dokumentet

10.1097/INF.0000000000003189

Citationsformater

@article{26d0ca81fa3c4089b883618255965597,

title = "Aspergillus flavus Infections in Children with Leukemia despite Liposomal Amphotericin-B Prophylaxis",

abstract = "Liposomal amphotericin-B (L-AmB) prophylaxis is used in children with leukemia when azoles are contraindicated, but its effect is debated. We reviewed cases of invasive aspergillosis despite L-AmB 2.5 mg/kg twice weekly in children with high-risk leukemia during 2012-2019. Ten (16%) of 62 children had proven or probable aspergillosis. Thus, L-AmB prophylaxis offered insufficient protection for Aspergillus, in particular for Aspergillus flavus. ",

keywords = "Aspergillus flavus, invasive fungal disease, pediatric leukemia, prophylaxis",

author = "Vissing, {Nadja Hawwa} and Birgitte Lausen and {Hutchings Hoffmann}, Marianne and Bodil Als-Nielsen and Kjeld Schmiegelow and Jannik Helweg-Larsen and Arendrup, {Maiken Cavling} and Ulrikka Nygaard",

year = "2021",

doi = "10.1097/INF.0000000000003189",

language = "English",

volume = "40",

pages = "749--752",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams & Wilkins",

number = "8",

}

TY - JOUR

T1 - Aspergillus flavus Infections in Children with Leukemia despite Liposomal Amphotericin-B Prophylaxis

AU - Vissing, Nadja Hawwa

AU - Lausen, Birgitte

AU - Hutchings Hoffmann, Marianne

AU - Als-Nielsen, Bodil

AU - Schmiegelow, Kjeld

AU - Helweg-Larsen, Jannik

AU - Arendrup, Maiken Cavling

AU - Nygaard, Ulrikka

PY - 2021

Y1 - 2021

N2 - Liposomal amphotericin-B (L-AmB) prophylaxis is used in children with leukemia when azoles are contraindicated, but its effect is debated. We reviewed cases of invasive aspergillosis despite L-AmB 2.5 mg/kg twice weekly in children with high-risk leukemia during 2012-2019. Ten (16%) of 62 children had proven or probable aspergillosis. Thus, L-AmB prophylaxis offered insufficient protection for Aspergillus, in particular for Aspergillus flavus.

AB - Liposomal amphotericin-B (L-AmB) prophylaxis is used in children with leukemia when azoles are contraindicated, but its effect is debated. We reviewed cases of invasive aspergillosis despite L-AmB 2.5 mg/kg twice weekly in children with high-risk leukemia during 2012-2019. Ten (16%) of 62 children had proven or probable aspergillosis. Thus, L-AmB prophylaxis offered insufficient protection for Aspergillus, in particular for Aspergillus flavus.

KW - Aspergillus flavus

KW - invasive fungal disease

KW - pediatric leukemia

KW - prophylaxis

U2 - 10.1097/INF.0000000000003189

DO - 10.1097/INF.0000000000003189

M3 - Journal article

C2 - 34250973

AN - SCOPUS:85110574413

SN - 0891-3668

VL - 40

SP - 749

EP - 752

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 8

ER -